Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.

[1]  Rosalia Viterbo,et al.  Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer , 2011, Cancer.

[2]  F. Mottaghy,et al.  Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. , 2011, European urology.

[3]  C. Simone.  Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95. , 2011, European urology.

[4]  U. Capitanio,et al.  Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. , 2011, European urology.

[5]  J. Kaouk,et al.  Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. , 2011, Urology.

[6]  P. Scardino,et al.  Pathological results and rates of treatment failure in high‐risk prostate cancer patients after radical prostatectomy , 2011, BJU international.

[7]  D. Penson,et al.  Trends in the treatment of localized prostate cancer using supplemented cancer registry data , 2011, BJU international.

[8]  M. Cooperberg,et al.  Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer , 2010, Cancer.

[9]  J. Eastham,et al.  What is the optimal management of high risk, clinically localized prostate cancer? , 2010, Urologic oncology.

[10]  B. Tombal,et al.  Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. , 2010, European urology.

[11]  P. Scardino,et al.  Variations among experienced surgeons in cancer control after open radical prostatectomy. , 2010, The Journal of urology.

[12]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Trock,et al.  What are the outcomes of radical prostatectomy for high-risk prostate cancer? , 2009, Urology.

[14]  C. Lawton.  Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .

[15]  J. Eastham,et al.  Role of radical prostatectomy in the treatment of high-risk prostate cancer , 2008, Current urology reports.

[16]  M. Kattan,et al.  Radical prostatectomy in men aged ≥70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram , 2008, BJU international.

[17]  F. Saad,et al.  Prostate volume and adverse prostate cancer features: fact not artifact. , 2007, European journal of cancer.

[18]  C. Roehrborn,et al.  Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. , 2007, European urology.

[19]  F. Montorsi,et al.  Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. , 2007, European urology.

[20]  P. Scardino,et al.  Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.

[21]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[22]  P. Scardino,et al.  Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. , 2006, The Journal of urology.

[23]  M. Zelefsky.  Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) , 2006 .

[24]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[25]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[26]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[27]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[28]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[29]  F. Montorsi,et al.  A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.

[30]  M. Cooperberg,et al.  Erratum: Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer , 2011 .

[31]  C. Lawton.  Duration of Androgen Suppression in the Treatment of Prostate Cancer , 2010 .

[32]  T. Roskams,et al.  Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. , 2007, European urology.